FDA Approved New Drug For Hot Flashes Menopause Treatment
Food and Drug Administration (FDA) recently approval new drug for Hot Flashes Menopause Treatment of moderate-to-severe vasomotor symptoms linked with menopause was distinctive for at least two reasons. First, it offered the first nonhormonal option to women who cannot or do not want to use hormonal medications for Hot Flashes Menopause Treatment.
Second, the approval ran counter to the recommendation of the FDA Reproductive Health Drugs Advisory Committee, which had concluded, by a vote of 10 to 4, that the overall benefit–risk profile of Brisdelle did not support approval. The FDA always carefully believed the advice from its advisory committees but is not required to follow the committee recommendations. Why did the FDA decide, despite a negative vote from an advisory committee, to approve Brisdelle?